| Literature DB >> 31875103 |
Hassan Hashemi1,2, Mohammad Saatchi1, Abbasali Yekta3, Babak Ali3, Hadi Ostadimoghaddam4, Payam Nabovati5, Mohamadreza Aghamirsalim6, Mehdi Khabazkhoob7.
Abstract
PURPOSE: To determine the prevalence of asthenopia and its associated factors in a sample of university students in Iran.Entities:
Keywords: Astigmatism; Photophobia; Prevalence; Asthenopia
Year: 2019 PMID: 31875103 PMCID: PMC6825687 DOI: 10.18502/jovr.v14i4.5455
Source DB: PubMed Journal: J Ophthalmic Vis Res ISSN: 2008-322X
The prevalence of asthenopia among 1,462 participants
|
| ||||||
| 70.9 (68.3–73.5) | 39.8 (36.4–43.1) | 19.7 (16.0–23.3) | ||||
|
| Male | 65.5 (60.8–70.2) | 0.048 | 31.6 (26.7–36.5) | 12.8 (9.8–15.8) | 389 |
| Female | 73.3 (70.5–76.1) | 43.8 (41.1–46.6) | 22.2 (18.6–25.9) | 1,073 | ||
|
| 18–19 | 72.2 (66.9–77.9) | 0.219 | 38.9 (30.5–47.3) | 23.3 (17.6–29.1) | 90 |
| 20–21 | 70.2 (65.5–75.0) | 37.2 (32.3–42.1) | 19.3 (13.5–25.0) | 441 | ||
| 22–23 | 71.6 (67.4–75.8) | 42.3 (38.2–46.4) | 18.5 (13.8–23.2) | 546 | ||
| 24–25 | 72.6 (66.8–79.4) | 42.4 (35.7–49.2) | 22.4 (16.4–28.5) | 205 | ||
| 26–27 | 75.3 (64.8–84.8) | 48.1 (31.6–64.5) | 23.4 (11.5-35.3) | 77 | ||
| 28–29 | 81.5 (66.2–96.9) | 55.3 (41.2–69.3) | 23.7 (14.9–32.5) | 38 | ||
|
| 58.4 (45.0–71.8) | 29.2 (16.5–41.9) | 13.8 (4.5–23.2) | 65 | ||
|
| Emmetropia | 70.2 (62.9–71.0) | <0.001 | 34.3 (29.5–32.9) | 15.5 (10.5–20.5) | 803 |
| Hyperopia | 79.6 (73.9–78.7) | 47.5 (44.8–50.1) | 24.6 (20.3–28.9) | 625 | ||
| Myopia | 79.4 (53.7–99.9) | 61.7 (35.4–88.0) | 29.4 (8.2–50.5) | 34 | ||
|
| No | 68.5 (65.9–71.1) | <0.001 | 36.7 (33.8–39.7) | 16.9 (12.8–21.0) | 1,030 |
| Yes | 77.7 (73.0–82.4) | 49.7 (45.0–54.4) | 26.3 (23.2–29.5) | 432 | ||
|
| Underweight | 72.7 (64.2–81.3) | 0.774 | 40.8 (28.5–53.1) | 21.0 (9.4–32.7) | 147 |
| Normal | 70.6 (66.9–74.4) | 40.3 (38.2–42.4) | 19.1 (16.2–22.0) | 986 | ||
| Overweight | 72.3 (68.2–76.4) | 41.6 (34.9–48.4) | 20.9 (16.3–25.5) | 329 | ||
|
| 1–4 ( | 72.4 (68.3–76.5) | 0.374 | 39.3 (35.5–43.1) | 20.0 (15.3–24.7) | 709 |
| > 4 (> 2 year) | 70.3 (66.7–73.8) | 41.8 (38.2–45.4) | 19.5 (14.4–24.5) | 753 | ||
|
| No | 70.5 (66.4–74.7) | 0.141 | 40.4 (37.5–43.3) | 19.2 (15.9–22.5) | 974 |
| Exo | 71.7 (68.3–75.2) | 39.8 (36.7–43.0) | 19.2 (13.8–24-7) | 467 | ||
| Eso | 86.8 (74.2–99.5) | 60.5 (43.7–77.3) | 34.9 (27.7–51.1) | 38 | ||
| Hyper | 57.1 (18.5–95.8) | 14.3(8.2–46.8) | 14.2 (8.2–46.7) | 7 | ||
|
| No | 70.9 (68.1–73.7) | 0.283 | 40.0 (37.3–42.8) | 19.3 (16.2–22.5) | 1,409 |
| Yes | 79.2 (63.3–95.1) | 54.7 (34.7–74.4) | 30.1 (16.2–44.1) | 53 | ||
| The presence of at least one of the 10 symptoms of foreign body sensation, diplopia, blurred vision, eye swelling, dry eye, eye pain, difficulty in sustaining visual operations, decreased visual acuity, tearing, and photophobia was considered as asthenopia. | ||||||
| BMI, body mass index; CI, confidence interval; Eso, esophoria; Exo, exophoria | ||||||
Prevalence of symptoms by gender
|
| ||||||
|
| ||||||
| 15.4 (12.4–18.5) | 10.5 (7.8–13.2) | 0.017 | ||||
|
| 7.5 (5.3–9.7) | 5.6 (3.7–7.5) | 0.211 | |||
|
| 6.4 (4.2–8.5) | 2.5 (0.9–4.1) | 0.004 | |||
|
| 23.6 (19.0–28.2) | 17.4 (14.2–20.7) | 0.012 | |||
|
| 8.39 (6.0–10.7) | 4.6 (2.9–6.3) | 0.015 | |||
|
| 11.4 (8.7–14.2) | 11.0 (7.9–14.2) | 0.827 | |||
|
| 51.8 (48.3–55.3) | 40.3 (32.3–48.3) |
| |||
|
| 30.0 (25.2–34.7) | 22.6 (16.5–28.7) | 0.005 | |||
|
| 2.1 (0.8–3.4) | 2.5 (1.4–3.7) | 0.627 | |||
| CI, confidence interval | ||||||
Simple and multi-variable logistic regression for the associated risk factors of asthenopia
|
| ||||||
| Female | 1.44 | 1.01–2.05 | 0.041 | |||
| Male | Reference | |||||
|
| ||||||
| 18–19 | 1.85 | 0.85–4.02 | 0.111 | 1.66 | 0.73–3.77 | 0.203 |
| 20–21 | 1.68 | 0.89–3.18 | 0.101 | 1.68 | 0.78–3.65 | 0.167 |
| 22–23 | 1.79 | 1.03–3.13 | 0.042 | 1.69 | 0.87–3.29 | 0.108 |
| 24–25 | 1.89 | 0.90–3.96 | 0.085 | 1.89 | 0.83–4.31 | 0.116 |
| 26–27 | 2.17 | 0.90–5.20 | 0.077 | 2.06 | 0.93–4.55 | 0.071 |
| 28–29 | 3.15 | 1.40–7.07 | 0.01 | 3.51 | 1.26–9.89 | 0.021 |
| ≥ 30 | Reference | Reference | ||||
|
| ||||||
| Emmetropia | Reference | |||||
| Myopia | 1.58 | 1.27–1.98 | 0.001 | |||
| Hyperopia | 1.89 | 0.38–9.35 | 0.394 | |||
|
| ||||||
| No | Reference | Reference | ||||
| Yes | 1.6 | 1.24–2.06 | 0.002 | 1.61 | 1.22–2.13 | 0.003 |
|
| ||||||
| Normal | Reference | |||||
| Underweight | 1.1 | 0.71–1.72 | 0.617 | |||
| Overweight | 1.08 | 079–1.48 | 0.584 | |||
|
| ||||||
| 1–4( | Reference | |||||
| > 4(> 2 year) | 0.9 | 0.69–1.17 | 0.418 | |||
|
| ||||||
| No | Reference | |||||
| Yes | 1.58 | 0.584.14 | 0.337 | |||
|
| ||||||
| No | Reference | |||||
| Eso | 1.06 | 0.79–1.42 | 0.671 | |||
| Exo | 2.76 | 0.98–7.75 | 0.054 | |||
| Hyper | 0.56 | 0.12–2.66 | 0.427 | |||
| AA (diopter) | 0.95 | 0.92–0.98 | 0.007 | |||
| NPC (cm) | 0.91 | 0.87–0.96 | < 0.002 | 0.91 | 0.86–0.97 | 0.008 |
| AA, accommodative amplitude; BMI, body mass index; NPC, near point of convergence; OR, odds ratio | ||||||